Stephen C. Farrell serves as President and Chief Executive Officer of STAAR Surgical Company, a global leader in the development, manufacture, and marketing of minimally invasive ophthalmic implants, including the flagship EVO Visian Implantable Collamer Lens (ICL). Farrell joined STAAR in 2014 as Chief Financial Officer, bringing over two decades of experience in the medical device and pharmaceutical industries. Prior to STAAR, he held senior financial and operational roles at Allergan, Inc., where he contributed to the company's growth in ophthalmology and aesthetics, including managing global finance for key product lines and leading mergers and acquisitions. In 2016, Farrell advanced to Chief Operating Officer, overseeing global operations, supply chain, and commercial strategies that positioned STAAR for accelerated expansion. He assumed the role of President and CEO in January 2017, steering the company through a period of remarkable transformation. Under his leadership, STAAR achieved record revenues, surpassing $150 million annually by 2023, driven by surging demand for EVO ICL procedures, particularly in high-growth markets like China and the United States. Key achievements include regulatory approvals for next-generation ICL products, strategic partnerships, and a focus on innovation that has solidified STAAR's position as the market leader in phakic IOLs. Farrell's strategic vision emphasizes patient safety, surgeon education, and sustainable growth, with initiatives like the EVO+ ICL launch enhancing accessibility and outcomes. A certified public accountant with a B.S. in Accounting from California State University, Fullerton, he continues to champion STAAR's mission to revolutionize vision correction, fostering a culture of excellence that has delivered consistent double-digit growth and strong shareholder value.